| Medical and Health Sciences | 2021-2025 | 257 | US 90 | 99.95 |
| Reproductive Medicine | Lifetime | 68 | US 30 | 99.63 |
| Oncology | Lifetime | 418 | US 238 | 99.28 |
| Obstetrics and Gynecology | Lifetime | 165 | US 76 | 98.96 |
| Reproductive Medicine | 2021-2025 | 4 | US 1 | 99.88 |
| Oncology | 2021-2025 | 73 | US 30 | 99.60 |
| Obstetrics and Gynecology | 2021-2025 | 130 | US 41 | 96.44 |
| Pulmonary and Respiratory Medicine | 2021-2025 | 629 | US 218 | 92.58 |
| Radiology, Nuclear Medicine and Imaging | 2021-2025 | 596 | US 207 | 87.11 |
| Ovarian cancer diagnosis and treatment | Lifetime | 40 | US 19 | 99.68 |
| Endometrial and Cervical Cancer Treatments | Lifetime | 60 | US 34 | 99.51 |
| PARP inhibition in cancer therapy | Lifetime | 34 | US 19 | 99.33 |
| Intraperitoneal and Appendiceal Malignancies | Lifetime | 70 | US 34 | 98.96 |
| Cervical Cancer and HPV Research | Lifetime | 285 | US 137 | 98.53 |
| Cancer Immunotherapy and Biomarkers | Lifetime | 828 | US 412 | 98.28 |
| HER2/EGFR in Cancer Research | Lifetime | 443 | US 208 | 98.13 |
| Advanced Breast Cancer Therapies | Lifetime | 248 | US 117 | 97.93 |
| BRCA gene mutations in cancer | Lifetime | 472 | US 252 | 96.85 |
| Renal cell carcinoma treatment | Lifetime | 767 | US 390 | 97.05 |
| Cancer Mechanisms and Therapy | Lifetime | 429 | US 188 | 95.70 |
| Toxin Mechanisms and Immunotoxins | Lifetime | 617 | US 304 | 95.26 |
| PI3K/AKT/mTOR signaling in cancer | Lifetime | 857 | US 458 | 94.06 |
| Aesthetic Perception and Analysis | Lifetime | 352 | US 134 | 85.06 |
| Ovarian cancer diagnosis and treatment | 2021-2025 | 5 | US 1 | 99.90 |
| PARP inhibition in cancer therapy | 2021-2025 | 7 | US 3 | 99.70 |
| Endometrial and Cervical Cancer Treatments | 2021-2025 | 62 | US 13 | 98.65 |
| Monoclonal and Polyclonal Antibodies Research | 2021-2025 | 167 | US 65 | 96.65 |
| BRCA gene mutations in cancer | 2021-2025 | 82 | US 39 | 96.49 |
| Intraperitoneal and Appendiceal Malignancies | 2021-2025 | 48 | US 7 | 95.76 |
| HER2/EGFR in Cancer Research | 2021-2025 | 203 | US 71 | 96.74 |
| Toxin Mechanisms and Immunotoxins | 2021-2025 | 60 | US 13 | 89.56 |
| Advanced Breast Cancer Therapies | 2021-2025 | 371 | US 137 | 93.32 |
| Lymphoma Diagnosis and Treatment | 2021-2025 | 880 | US 357 | 92.79 |
| Cancer Mechanisms and Therapy | 2021-2025 | 229 | US 31 | 88.15 |
| Cervical Cancer and HPV Research | 2021-2025 | 727 | US 220 | 88.30 |
| Renal cell carcinoma treatment | 2021-2025 | 963 | US 301 | 87.96 |
| Genetic factors in colorectal cancer | 2021-2025 | 919 | US 295 | 86.38 |
| Colorectal and Anal Carcinomas | 2021-2025 | 654 | US 164 | 86.23 |
| Chromatin Remodeling and Cancer | 2021-2025 | 288 | US 125 | 75.29 |
